We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Quaker Chemical (KWR) Down 23.3% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
It has been about a month since the last earnings report for Quaker Chemical (KWR - Free Report) . Shares have lost about 23.3% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Quaker Chemical due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Quaker Houghton before we dive into how investors and analysts have reacted as of late.
Key Highlights
Earnings per share (as reported) for the fourth quarter of 2025 were $1.18 compared with 81 cents a year ago, up 45.5%.
Adjusted earnings per share rose 24% to $1.65 from $1.33 in the prior-year quarter. It missed the Zacks Consensus Estimate of $1.71.
Revenues were $468.5 million, up 5.5% year over year from $444.1 million in the year-ago quarter. It beat the consensus estimate of $465.3 million.
Top-line growth in the fourth quarter was broad-based with important mix effects. Management attributes the sales increase primarily to acquisitions and favorable currency swings, partly offset by unfavorable price/mix and lower organic volume.
Adjusted EBITDA was $71.9 million compared with $64.8 million, up 10.9%, with an adjusted EBITDA margin of 15.3% compared with 14.6% a year ago.
Segment Performance
Americas: Net sales were $207.8 million, essentially flat year over year. Volumes declined 4%, offset by favorable currency of 2% and the contribution of acquisitions of 2%. Segment operating earnings increased modestly to $51.2 million from $50.9 million.
EMEA: Net sales were $135 million, up 7.3% year over year, driven by acquisitions, favorable price/mix, and currency, while volumes declined 2%. Segment operating earnings increased to $21.8 million from $18.6 million.
Asia/Pacific: Net sales were $125.7 million, up 14.7% year over year. Organic volume rose 4% and acquisitions, primarily Dipsol, provided a meaningful lift. Segment operating earnings increased to $34 million from $30.7 million.
Balance Sheet, Cash Flow and Capital Deployment
Fourth-quarter operating cash flow was $47 million versus $63 million a year ago, reflecting higher restructuring outflows and working capital needs, including temporary inventory builds in EMEA to support network optimization. Full-year operating cash flow was $136.5 million.
As of Dec 31, 205, total debt stood at $871 million, cash at $180 million and net debt at $691 million. Net leverage was 2.3x TTM adjusted EBITDA.
The company repurchased approximately $5 million of stock in the quarter and $41.5 million for the full year, and paid $34 million in dividends.
Outlook
Management expects first-quarter 2026 to mark a third consecutive quarter of year-over-year EBITDA improvement, supported by share gains, gross margin recovery from the fourth quarter's operational issues, and acquisition run-rate.
For 2026, the outlook calls for mid-single-digit revenue growth and high-single-digit adjusted EBITDA growth, with gross margin targeted at 36-37% for the year. Share gains of 2-4% are expected across all regions, with Asia/Pacific remaining the growth leader.
SG&A is expected to be higher year over year due to variable compensation rebuild and inflation, partially offset by transformation and cost-structure initiatives. Capital expenditure is planned at 2.5-3.5% of sales, including completion of a new China facility targeted to begin operations in the second half and the 2026 consolidation.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates review.
The consensus estimate has shifted -7.37% due to these changes.
VGM Scores
At this time, Quaker Chemical has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. Charting a somewhat similar path, the stock has a score of B on the value side, putting it in the second quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Quaker Chemical has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
Performance of an Industry Player
Quaker Chemical belongs to the Zacks Chemical - Specialty industry. Another stock from the same industry, Celanese (CE - Free Report) , has gained 14.5% over the past month. More than a month has passed since the company reported results for the quarter ended December 2025.
Celanese reported revenues of $2.2 billion in the last reported quarter, representing a year-over-year change of -7%. EPS of $0.67 for the same period compares with $1.45 a year ago.
For the current quarter, Celanese is expected to post earnings of $0.81 per share, indicating a change of +42.1% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.2% over the last 30 days.
Celanese has a Zacks Rank #5 (Strong Sell) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Quaker Chemical (KWR) Down 23.3% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Quaker Chemical (KWR - Free Report) . Shares have lost about 23.3% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Quaker Chemical due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Quaker Houghton before we dive into how investors and analysts have reacted as of late.
Key Highlights
Earnings per share (as reported) for the fourth quarter of 2025 were $1.18 compared with 81 cents a year ago, up 45.5%.
Adjusted earnings per share rose 24% to $1.65 from $1.33 in the prior-year quarter. It missed the Zacks Consensus Estimate of $1.71.
Revenues were $468.5 million, up 5.5% year over year from $444.1 million in the year-ago quarter. It beat the consensus estimate of $465.3 million.
Top-line growth in the fourth quarter was broad-based with important mix effects. Management attributes the sales increase primarily to acquisitions and favorable currency swings, partly offset by unfavorable price/mix and lower organic volume.
Adjusted EBITDA was $71.9 million compared with $64.8 million, up 10.9%, with an adjusted EBITDA margin of 15.3% compared with 14.6% a year ago.
Segment Performance
Americas: Net sales were $207.8 million, essentially flat year over year. Volumes declined 4%, offset by favorable currency of 2% and the contribution of acquisitions of 2%. Segment operating earnings increased modestly to $51.2 million from $50.9 million.
EMEA: Net sales were $135 million, up 7.3% year over year, driven by acquisitions, favorable price/mix, and currency, while volumes declined 2%. Segment operating earnings increased to $21.8 million from $18.6 million.
Asia/Pacific: Net sales were $125.7 million, up 14.7% year over year. Organic volume rose 4% and acquisitions, primarily Dipsol, provided a meaningful lift. Segment operating earnings increased to $34 million from $30.7 million.
Balance Sheet, Cash Flow and Capital Deployment
Fourth-quarter operating cash flow was $47 million versus $63 million a year ago, reflecting higher restructuring outflows and working capital needs, including temporary inventory builds in EMEA to support network optimization. Full-year operating cash flow was $136.5 million.
As of Dec 31, 205, total debt stood at $871 million, cash at $180 million and net debt at $691 million. Net leverage was 2.3x TTM adjusted EBITDA.
The company repurchased approximately $5 million of stock in the quarter and $41.5 million for the full year, and paid $34 million in dividends.
Outlook
Management expects first-quarter 2026 to mark a third consecutive quarter of year-over-year EBITDA improvement, supported by share gains, gross margin recovery from the fourth quarter's operational issues, and acquisition run-rate.
For 2026, the outlook calls for mid-single-digit revenue growth and high-single-digit adjusted EBITDA growth, with gross margin targeted at 36-37% for the year. Share gains of 2-4% are expected across all regions, with Asia/Pacific remaining the growth leader.
SG&A is expected to be higher year over year due to variable compensation rebuild and inflation, partially offset by transformation and cost-structure initiatives. Capital expenditure is planned at 2.5-3.5% of sales, including completion of a new China facility targeted to begin operations in the second half and the 2026 consolidation.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates review.
The consensus estimate has shifted -7.37% due to these changes.
VGM Scores
At this time, Quaker Chemical has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. Charting a somewhat similar path, the stock has a score of B on the value side, putting it in the second quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Quaker Chemical has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
Performance of an Industry Player
Quaker Chemical belongs to the Zacks Chemical - Specialty industry. Another stock from the same industry, Celanese (CE - Free Report) , has gained 14.5% over the past month. More than a month has passed since the company reported results for the quarter ended December 2025.
Celanese reported revenues of $2.2 billion in the last reported quarter, representing a year-over-year change of -7%. EPS of $0.67 for the same period compares with $1.45 a year ago.
For the current quarter, Celanese is expected to post earnings of $0.81 per share, indicating a change of +42.1% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.2% over the last 30 days.
Celanese has a Zacks Rank #5 (Strong Sell) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.